Many supplements are available to the general public for a limited time on our SuppleNet page.
VOLUME 59 1998 SUPPLEMENT 12
Articles
3 Measuring Outcome in Schizophrenia:
Differences Among the Atypical Antipsychotics. Collaborative Working Group on Clinical Trial Evaluations
[Abstract]
[PDF]
10 Clinical Development of Atypical Antipsychotics:
Research Design and Evaluation. Collaborative Working Group on Clinical Trial Evaluations
[Abstract]
[PDF]
17 Adverse Effects of the Atypical Antipsychotics. Collaborative Working Group on Clinical Trial Evaluations
[Abstract]
[PDF]
23 Assessment of EPS
and Tardive Dyskinesia in Clinical Trials. Collaborative Working Group on Clinical Trial Evaluations
[Abstract]
[PDF]
28 Assessing the Effects of
Atypical Antipsychotics on Negative Symptoms. Collaborative Working Group on Clinical Trial Evaluations
[Abstract]
[PDF]
35 Evaluating the Effects of Antipsychotics
on Cognition in Schizophrenia. Collaborative Working Group on Clinical Trial Evaluations
[Abstract]
[PDF]
41 Atypical Antipsychotics for Treatment of Depression
in Schizophrenia and Affective Disorders. Collaborative Working Group on Clinical Trial Evaluations
[Abstract]
[PDF]
46 Treatment of Special Populations
With the Atypical Antipsychotics. Collaborative Working Group on Clinical Trial Evaluations
[Abstract]
[PDF]
CME Section
53 Instructions and Posttest.
[PDF]
55 Registration and Evaluation.
[PDF]